 Celldex Therapeutics, Inc. CLDX today announced results from the Companys Phase 1 randomized, double-blind, placebo-controlled, dose escalation study of KIT inhibitor CDX-0159 in healthy subjects. Data presentation 1829 were featured in a late breaking presentation today at the European Academy of Allergy and Clinical Immunology EAACI Annual Congress 2020. CDX-0159 demonstrated a favorable safety profile as well as profound and durable reductions of plasma tryptase, consistent with systemic mast cell suppression. 